Radiotherapy-induced dermatitis (RID) develops almost in all breast cancer patients with 30-40% of women developing moderate and severe forms (i.e., grade 2 or higher).
Alopecia, the partial or complete lost of hair, is a frequent consequence of breast cancer therapy and can be psychologically and socially devastating. Between 40% and 100% of patients with breast cancer experience complete alopecia during chemotherapy, and the remainder experience some degree of hair thinning or weakening. Most patients with breast cancer consider hair loss as the most traumatic aspect of chemotherapy, and up to 8% reject chemotherapy because of extreme anxiety related to chemotherapy-induced alopecia (CIA).
Tarian Pharma’s priority is to develop medicines that prevent radiation–induced dermatitis and chemotherapy–induced alopecia in breast cancer patients.
